Expression data from Lung cancer

Detection, treatment, and prediction of outcome for lung cancer patients increasingly depend on a molecular understanding of tumor development and sensitivity of lung cancer to therapeutic drugs. The application of genomic technologies, such as microarray, is widely used to monitor global gene expression and has built up invaluable information and knowledge, which is essential to the discovery of new insights into the mechanisms common to cancer cells, resulting in the identification of unique, identifiable signatures and specific characteristics. It is likely that application of microarray may revolutionize many aspects of lung cancer being diagnosed, classified, and treated in the near future. We used microarrays to detail the global gene expression patterns of lung cancer. Keywords: Disease state analysis Adjacent normal-tumor matched lung cancer samples were selected at early and late stages for RNA extraction and hybridization on Affymetrix microarrays. A total of 66 samples were used for microarray analysis, including pairwise samples from 27 patients, who underwent surgery for lung cancer at the Taipei Veterans General Hospital, two tissue mixtures from the Taichung Veterans General Hospital (one was adjacent normal lung mixtures and the other was lung adenocarcinoma mixtures), two commercial human normal lung tissues (Clontech (Catalog No. 636524) and Stratagene (Catalog No. 735020)), one immortalized, nontumorigenic human bronchial epithelial cell line (NL-20 (ATCC® No. CRL-2503)), and 7 lung cancer cell lines (A-549 (ATCC® No. CCL-185), NCI-H1299 (ATCC® No. CRL-5803), NCI-H661 (ATCC® No. HTB-183), CL1-0, CL1-1, CL1-5 and CL1-5-F4.